IDH1 and acute myeloid leukemia: It is worth to mention that the discovery of IDH inhibitors such as Ivosidenib and Enasidenib, specifically targeting the IDH1 and IDH2 proteins, respectively, has opened up new opportunities for targeted therapy in AML, showing great promise for improving patient outcomes [22, 24].